BIBLIOGRAFIA:
1.Banegas JR, Rodríguez-Artalejo F, Graciani A, Villar F, Herruzo R. Mortality attributable to cardiovascular risk factors in Spain.Eur J ClinNutr. 2003 Sep;57Suppl 1:S18-21.

2. Saez M, Barceló MA. Coste de la hipertensión arterial en España. HipertensRiesgoVasc. 2012;29:145-51.

3. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Böhm M, et al. Task Force for the Management of Arterial Hypertension of the European Society of Hypertension and the European Society of Cardiology. 2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension.Blood Press. 2014 Feb;23(1):3-16.

4. Gradman AH, Basile JN, Carter BL, Bakris GL, Materson BJ, Black HR, Izzo JL Jr, Oparil S, Weber MA. Combination therapy in hypertension. J Am SocHypertens. 2010 Mar-Apr;4(2):90-8.

5. Panjabi S, Lacey M, Bancroft T, Cao F. Treatment adherence, clinical outcomes, and economics of triple-drug therapy in hypertensive patients. J Am SocHypertens. 2013 Jan-Feb;7(1):46-60.

6. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009 Mar;122(3):290-300.